PMH23 COST-EFFECTIVENESS OF OLANZAPINE VERSUS GENERIC RISPERIDONE AND OTHER ANTIPSYCHOTICS IN STANDARD ORAL FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA IN THE US
Abstract
Authors
H Ascher-Svanum NM Furiak RW Klein LJ Smolen B Zhu